The times they are a-changin': Time to change glaucoma management

Acta Ophthalmologica

Volumn 91, Issue 1, 2013, Pages 92-99

  Heijl, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; BLINDNESS; CLINICAL RESEARCH; CONFOCAL LASER TOMOGRAPHY; DISEASE COURSE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PERIMETRY; PERSONALIZED MEDICINE; POLARIMETRY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY; VISION TEST; VISUAL FIELD;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FILTERING SURGERY; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANTS; HUMANS; INDIVIDUALIZED MEDICINE; INTRAOCULAR PRESSURE; QUALITY OF LIFE; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84873058012     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02328.x     Document Type: Review

References (42)

1. Advanced Glaucoma Intervention Study Group (1994): The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 15: 299-325.
2. AGIS Investigators (2000): The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
3. Anderson DR, Drance SM, &, Schulzer M, (2001): Natural history of normal-tension glaucoma. Ophthalmology 108: 247-253.
4. Bengtsson B, &, Heijl A, (2008): A visual field index for calculation of glaucoma rate of progression. Am J Ophthalmol 145: 343-353.
5. Bengtsson B, Lindgren A, Heijl A, Lindgren G, Åsman P, Patella M, (1997): Perimetric probability maps to separate change caused by glaucoma from that caused by cataract. Acta Ophthalmol Scand 75: 184-188.
6. Bengtsson B, Patella VM, &, Heijl A, (2009): Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol 127: 1610-1615.
7. Bengtsson B, Andersson S, &, Heijl A, (2010): Performance of time-domain and spectral-domain Optical Coherence Tomography for glaucoma screening. Acta Ophthalmol. [Epub ahead of print].
8. Chauhan BC, et al., (2001): Optic disc and visual field changes in a prospective longitudinal study of patients with glaucoma: comparison of scanning laser tomography with conventional perimetry and optic disc photography. Arch Ophthalmol 119: 1492-1499.
9. Chauhan BC, et al., (2008a): Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 126: 1030-1036.
10. Chauhan BC, et al., (2008b): Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 92: 569-573.
11. Collaborative Normal-Tension Glaucoma Study Group (1998): The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126: 498-505.
12. European Glaucoma Society (2008): Terminology and guidelines for glaucoma, 3rd edn. Savona: Editrice Dogam S.r.l.
13. Fitzke FW, et al., (1996): Analysis of visual field progression in glaucoma. Br J Ophthalmol 80: 40-48.
14. Forsman E, Kivela T, &, Vesti E, (2007): Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 16: 313-319.
15. van Gestel A, et al., (2010): The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye 24: 1759-1769.
16. Gordon MO, &, Kass MA, (1999): The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 117: 573-583.
17. Gordon MO, et al., (2002): The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 714-720; discussion 829-30.
18. Grødum K, Heijl A, &, Bengtsson B, (2002): A comparison of glaucoma patients identified through mass screening and in routine clinical practice. Acta Ophthalmol Scand 80: 627-631.
19. Hattenhauer MG, et al., (1998): The probability of blindness from open-angle glaucoma. Ophthalmology 105: 2099-2104.
20. Heijl A, et al., (2002): Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.
21. Heijl A, et al., (2003): Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 81: 286-293.
22. Heijl A, et al., (2008): A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology 115: 1557-1565.
23. Heijl A, et al., (2009): Natural history of open-angle glaucoma. Ophthalmology 116: 2271-2276.
24. Heijl A, Alm A, Bengtsson B, Bergström A, Calissendorff B, Lindblom B, &, Lindén C, (2010): Riktlinjer för glaukomsjukvården. Malmö: Sveriges Ögonläkarförening, Bäcklunds media.
25. Hyman LG, et al., (2005): Treatment and vision-related quality of life in the early manifest glaucoma tria'. Ophthalmology 112: 1505-1513.
26. Jampel HD, et al., (2006): Test-retest variability in structural and functional parameters of glaucoma damage in the glaucoma imaging longitudinal study. J Glaucoma 15: 152-157.
27. Kass MA, et al., (2002): The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713; discussion 829-30.
28. Leske MC, et al., (1999): Early Manifest Glaucoma Trial: design and baseline data'. Ophthalmology 106: 2144-2153.
29. Leske MC, et al., (2003): Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121: 48-56.
30. Leske MC, et al., (2007): Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 114: 1965-1972.
31. Leung CK, et al., (2008): Longitudinal variability of optic disc and retinal nerve fiber layer measurements. Invest Ophthalmol Vis Sci 49: 4886-4892.
32. Leung CK, et al., (2011): Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression. Ophthalmology 118: 1551-1557.
33. Lindén C, Alm A, Bengtsson B, Calissendorff B, &, Heijl A, (2011): Glaucoma management in Sweden-results from a nationwide survey. Acta Ophthalmol. [Epub ahead of print].
34. Miglior S, et al., (2002): The European glaucoma prevention study design and baseline description of the participants. Ophthalmology 109: 1612-1621.
35. Miglior S, et al., (2007): Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 114: 3-9.
36. Musch DC, et al., (1999): The Collaborative Initial Glaucoma Treatment Study: study design, methods and baseline characteristics of enrolled patients. Ophthalmology 106: 653-662.
37. Quigley HA, et al., (1996): Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol 122: 355-363.
38. Quigley HA, Friedman DS, &, Hahn SR, (2007): Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 114: 1599-1606.
39. Sawada H, Fukuchi T, &, Abe H, (2011): Evaluation of the relationship between quality of vision and the visual function index in Japanese glaucoma patients. Graefes Arch Clin Exp Ophthalmol 249: 1721-1727.
40. Wändell PE, et al., (1997): Quality of life among patients with glaucoma in Sweden. Acta Ophthalmol Scand 75: 584-588.
41. Wren PA, et al., (2009): Contrasting the use of 2 vision-specific quality of life questionnaires in subjects with open-angle glaucoma. J Glaucoma 18: 403-411.
42. Wu SY, et al., (2008): Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci 49: 1333-1338.